GlobeNewswire

Clariant AG: Clariant signs an agreement regarding the sale of its Healthcare Packaging Business

Share
  • Divestment of Clariant’s Healthcare Packaging Business to Arsenal Capital Partners
  • Total consideration of approx. CHF 308 million
 
 

Muttenz, July 22, 2019 - Clariant, a focused and innovative specialty chemical company, has signed an agreement with respect to the sale of its Healthcare Packaging business to a newly-formed affiliate of Arsenal Capital Partners. The total consideration of the sale amounts to approximately CHF 308 million payable at closing, which is expected in Q4 2019. The total consideration is equivalent to 13.2 times adjusted FY2018 EBITDA. The closing of the transaction is subject to customary conditions and approvals.

Clariant’s Healthcare Packaging business offers products used to protect pharmaceutical products from moisture and oxygen.  This includes customizable, high-quality drop-in products (canisters and packets), Integrated Desiccant Systems and specially designed plastic bottles containing oxygen barrier materials. In 2018, the Healthcare Packaging business generated sales of around CHF 135 million. The business has manufacturing facilities in the USA, France, China and India and employs around 600 employees.

CORPORATE MEDIA RELATIONS INVESTOR RELATIONS
 

Jochen Dubiel

Phone +41 61 469 63 63
jochen.dubiel@clariant.com
Anja Pomrehn

Phone +41 61 469 67 45
anja.pomrehn@clariant.com
Claudia Kamensky

Phone +41 61 469 63 63
claudia.kamensky@clariant.com
Maria Ivek

Phone +41 61 469 63 73
maria.ivek@clariant.com
Thijs Bouwens

Phone +41 61 469 63 63
Thijs.bouwens@clariant.com
 
Follow us on Twitter, Facebook, Google Plus, LinkedIn.  
 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.

 

 

www.clariant.com

 

 

Clariant is a focused and innovative specialty chemical company, based in Muttenz near Basel/Switzerland. On 31 December 2018 the company employed a total workforce of 17 901. In the financial year 2018, Clariant recorded sales of CHF 6.623 billion for its continuing businesses. The company reports in four business areas: Care Chemicals, Catalysis, Natural Resources, and Plastics & Coatings. Clariant’s corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.


Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 20196.12.2019 22:30:00 CETPress release

Geneva, Switzerland and Boston, MA –December 6, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it will release results from the Phase 3 PRIMROSE 2 clinical trial of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids, on Monday December 9, 2019. ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, Monday December 9, 2019, to discuss these results. Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to conference ID 1764134. A webcast of the conference call can be accessed under the “Investors” section of ObsEva’s website www.obseva.com. About ObsEva ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics

OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS6.12.2019 17:45:00 CETPress release

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS The deadline for submission of all tenders is January 10th, 2020 before 04:00pm Paris and Boston, December 6th, 2019 – 05h45pm CET - Neovacs (Euronext Growth Paris : ALNEV) announces the launch of a call for tender opened from now until January 10th, 2020 before 4:00 pm, to provide a continuation plan through partners or investors (articles L.626-1 and L.626-3 of the French Commercial code) or a sale plan by one or more buyers (Articles L.642-1 et seq. of the French Commercial Code). Candidates are invited to submit their offer before January 10th, 2020 at 04:00pm at the following law office: SELARL 2M and associates, to Maître Carole Martinez, judicial administrator, 22 rue de l'Arcade 75008 Paris, France. Email: a.dekoninck@aj-2m.com Access to information for auditing the company (electronic data room), will b

Conditions for Riksbank Bid Procedures Sek Bonds6.12.2019 16:20:00 CETPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2019-12-12 Maturity date Loan ISIN code Coupon Volume, SEK million 2022-06-01 1054 SE0003784461 3.50 % 500 +/- 250 2029-11-12 1061 SE0011281922 0.75 % 500 +/- 250 Settlement date 2019-12-16 Bids have to be entered by 10.00 on DEC 12, 2019 Highest permitted bid volume: 500 SEK million in issue SGB 1054 and 500 SEK million in issue SGB 1061 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CET) ON DEC 12, 2019. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

Result of AGM6.12.2019 16:15:00 CETPress release

6 December 2019 Volta Finance Limited (VTA / VTAS) RESULTS OF THE THIRTEENTH ANNUAL GENERAL MEETING Volta Finance Limited announces that at the Thirteenth Annual General Meeting held earlier today all resolutions proposed were duly passed. Two of these resolutions were special resolutions. The full text of the resolutions can be found in the Notice of Meeting contained with the Annual Report and Accounts 2019, copies of which are available for viewing at on the Company’s website http://www.voltafinance.com The Board notes the votes against the resolutions to approve the re-election of the directors, Graham Harrison, Stephen Le Page, Paul Meader, Atosa Moini and Paul Varotsis, contained in resolutions 4 to 8 inclusive. The votes against each resolution equate to 37.05% of the total voted by proxy. The Board, through the Chair, AXA Investment Manager and the Company’s corporate broker, seeks to maintain an ongoing dialogue with major shareholders, including dissenting shareholders, and w

Beter Bed Holding announces sale and lease-back of the distribution centers in Hoogeveen and Nieuw-Vennep6.12.2019 15:00:00 CETPress release

Highlights: Beter Beheer B.V., the wholly owned subsidiary of Beter Bed Holding, has entered into two separate sale-and-leaseback transactions for its properties in Hoogeveen and Nieuw-Vennep for a cash consideration of in total € 5.1 million. The total book profit on these transactions is circa € 1.6 million after tax. Together with the previously announced sale-and-leaseback transaction of the property in Uden (Linie 27), these transactions show that the Benelux operations of Beter Bed Holding will continue operating in its current logistical structure. These transactions contribute to the improvement of the net debt position of Beter Bed Holding, because the proceeds will be used to repay bank debt. Together with the divestment of Matratzen Concord that was completed on 2 December, these transactions are important steps for the transformation of Beter Bed Holding. John Kruijssen, CEO of Beter Bed Holding, comments: “With these sale-and-leaseback transactions and the divestment of Ma

Changes in ownership6.12.2019 14:43:00 CETPress release

06 December 2019 Changes in ownership Redbrick Investments S.a.r.l. (Luxemburg) increased its stake in PJSC Acron to 62.65% from 62.48% by purchasing shares from JSC Agronova that decreased its stake to 0.15%. Media contacts: Sergey Dorofeev Anastasiya Gromova Tatiana Smirnova Public Relations Phone: +7 (495) 777-08-65 (ext. 5196) Investor contacts: Ilya Popov Investor Relations Phone: +7 (495) 745-77-45 (ext. 5252) Background Information Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and the Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is implementing a potash development project in Perm Krai (Verkhnekamsk Potash Company, VPC). It owns transportation and logistics infrastructure, including three Baltic port terminals and distribution networks in Russia and China. Acron’s subsidi